Total trials
637
Active
154
Phase 3
56
Total enrollment
33,178,916
Pipeline matrix
Showing 40 of 84 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Carboplatin | — | — | — | — | 4 | ||
| Rifampicin | — | — | — | — | 3 | ||
| Isoniazid | — | — | — | — | 3 | ||
| Pyrazinamide | — | — | — | — | 3 | ||
| Ethambutol | — | — | — | — | 3 | ||
| Dexamethasone | — | — | — | — | 3 | ||
| Durvalumab | — | — | — | — | 2 | ||
| cisplatin | — | — | — | 8 | |||
| Paclitaxel | — | — | — | — | — | 2 | |
| docetaxel | — | — | — | — | 2 | ||
| dacarbazine | — | — | — | — | — | 2 | |
| Semaglutide 3 mg | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| Ambroxol Hydrochloride | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | — | 1 | |
| Bleomycin | — | — | — | — | — | 1 | |
| Brentuximab vedotin | — | — | — | — | — | 1 | |
| Vinblastine | — | — | — | — | — | 1 | |
| Haematopoietic growth factor | — | — | — | — | — | 1 | |
| Tremelimumab | — | — | — | — | — | 1 | |
| Aspirin 100mg | — | — | — | — | — | 1 | |
| Aspirin 300mg | — | — | — | — | — | 1 | |
| Telmisartan | — | — | — | — | — | 1 | |
| Terazosin | — | — | — | — | — | 1 | |
| Nicotinomide | — | — | — | — | — | 1 | |
| Dexamethasone, cyclophosphamide, rituximab | — | — | — | — | — | 1 | |
| Rituximab, ibrutinib | — | — | — | — | — | 1 | |
| Androgen Deprivation Therapy | — | — | — | — | — | 1 | |
| Androgen Receptor Signalling Inhibitor | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 8 | |
| Rituximab | — | — | — | 10 | |||
| Linezolid | — | — | — | — | 2 | ||
| Bedaquiline | — | — | — | — | 2 | ||
| Moxifloxacin | — | — | — | — | 2 | ||
| 5-ALA | — | — | — | — | — | 2 | |
| Lu-177 DOTATATE | — | — | — | — | — | 1 | |
| Actinium (225Ac) rhPSMA-10.1 | — | — | — | — | — | 1 | |
| Ganfeborole | — | — | — | — | — | 1 | |
| BTZ-043 | — | — | — | — | — | 1 | |
| Delamanid | — | — | — | — | — | 1 |
44 more active programs hidden
Next readouts
- 2019-11
- 2022-06-20
- 2023-09-01
- 2024-01-10
- 2024-07-01
- 2024-08-15
- 2024-11
- 2024-12
- 2025-03
- 2025-12
Top conditions
- Stroke25
- Prostate Cancer23
- Heart Failure18
- Dementia16
- Lymphoma14
- Lung Cancer12
- Peripheral Arterial Disease10
- Obesity10
Frequently asked questions about University College, London
- How many clinical trials does University College, London have on ClinicalTrials.gov?
- University College, London is listed as the lead sponsor on 637 clinical trials in ClinicalTrials.gov, 154 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University College, London's trials are in Phase 3?
- 56 of University College, London's trials are in Phase 3, spread across 84 active drug programs.
- What therapeutic areas does University College, London focus on?
- University College, London's most-studied conditions on ClinicalTrials.gov are Stroke, Prostate Cancer, Heart Failure, Dementia, Lymphoma.
- When are University College, London's next clinical trial readouts?
- University College, London has 10 upcoming primary-completion readouts tracked here; the soonest is “Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma”, expected around 2019-11.